Ces 10 à 20 dernières années, on a pu observer une explosion des unités de soins Alzheimer qu’il s’agisse d’unités de soins Alzheimer dans des EHPAD, d’UHR, d’unités cognitivo-comportementales, de consultations mémoire, de CMRR, de PASA, de MAIA, d’ESA… Une… Continue Reading →
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT? P.S. Aisen J Prev Alz Dis 2019;6(3):150 EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE? J.C. Morris J Prev Alz Dis 2019;6(3):153-154 COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF… Continue Reading →
Background: Pimavanserin is a 5-HT2A receptor inverse agonist/antagonist and is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Objective: Evaluate the efficacy of pimavanserin on symptoms of psychosis in patients with Alzheimer’s… Continue Reading →
© 2025 Année gérontologique
